Cytokinetics (CYTK)
(Real Time Quote from BATS)
$52.13 USD
-1.64 (-3.05%)
Updated Sep 23, 2024 03:55 PM ET
After-Market: $52.10 -0.03 (-0.06%) 4:18 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Income Statements
Fiscal Year end for Cytokinetics, Incorporated falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 8 | 95 | 70 | 56 | 27 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 8 | 95 | 70 | 56 | 27 |
Selling & Adminstrative & Depr. & Amort Expenses | 504 | 419 | 257 | 150 | 126 |
Income After Depreciation & Amortization | -496 | -324 | -186 | -94 | -99 |
Non-Operating Income | 28 | -14 | 0 | 5 | 5 |
Interest Expense | 58 | 51 | 29 | 39 | 27 |
Pretax Income | -526 | -389 | -215 | -127 | -122 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -526 | -389 | -215 | -127 | -122 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -526 | -389 | -215 | -127 | -122 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -484 | -318 | -184 | -92 | -98 |
Depreciation & Amortization (Cash Flow) | 12 | 6 | 2 | 2 | 1 |
Income After Depreciation & Amortization | -496 | -324 | -186 | -94 | -99 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 96.52 | 89.83 | 76.89 | 64.52 | 57.58 |
Diluted EPS Before Non-Recurring Items | -5.45 | -4.06 | -2.80 | -1.97 | -2.11 |
Diluted Net EPS (GAAP) | -5.45 | -4.33 | -2.80 | -1.97 | -2.11 |
Fiscal Year end for Cytokinetics, Incorporated falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.25 | 0.84 | 1.67 | 0.38 | 0.87 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.25 | 0.84 | 1.67 | 0.38 | 0.87 |
SG&A, R&D, and Dept/Amort Expenses | 130.42 | 127.07 | 129.09 | 122.64 | 122.91 |
Income After SG&A, R&D, and Dept/Amort Expenses | -130.17 | -126.23 | -127.42 | -122.26 | -122.04 |
Non-Operating Income | 11.15 | 7.91 | 7.59 | 6.84 | 6.78 |
Interest Expense | 24.30 | 17.32 | 17.06 | 14.00 | 13.37 |
Pretax Income | -143.32 | -135.64 | -136.90 | -129.42 | -128.64 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -143.32 | -135.64 | -136.90 | -129.42 | -128.64 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -143.32 | -135.64 | -136.90 | -129.42 | -128.64 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 109.24 | 101.92 | 99.07 | 96.07 | 95.76 |
Diluted EPS Before Non-Recurring Items | -1.31 | -1.33 | -1.38 | -1.35 | -1.34 |
Diluted Net EPS (GAAP) | -1.31 | -1.33 | -1.38 | -1.35 | -1.34 |